John Wyeth Brother, Limited

American Home Products Corporation

Albert Opalko

Roger Crossley

Terence J Ward

John Leheup Archibald

Barry John Langham

Robin G Shepherd

Richard J Yarwood

Peter J Meade

Gerald Bradley

David Geraint Owen

Geoffrey P Carr

Brian Robertson

This invention concerns peptides (I) having intracellular potassium channel modulating activity comprising the amino acid sequence shown in SEQ ID No: 2:

Potassium channel modulators

Nitrogen heterocycles

Cyclohexane derivatives

This invention concerns compounds having the Z-configuration of formula: ##STR1## or salts thereof, wherein R represents an optionally substituted aryl or heteroaryl radical, R.sup.1, R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, (C.sub.1 -C.sub.6 alkoxy)carbonyl, carboxy, hydroxy (C.sub.1 -C.sub.6)alkyl, halogen, halo(C.sub.1 -C.sub.6)alkyl, carboxy(C.sub.1 -C.sub.6)alkyl, optionally substituted aryl or heteroaryl or optionally substituted aralkyl or heteroarylalkyl; n represents 0, 1 or 2; R.sup.4 and R.sup.5 each independently represent hydrogen or a substituent selected from lower alkyl, optionally substituted aryl and optionally substituted aralkyl or R.sup.4 and R.sup.5 are geminal C.sub.1 -C.sub.6 alkyl substituents and R.sup.6 is hydrogen or C.sub.1 -C.sub.6 alkyl which possess antiinflammatory activity.

Z-benzylidene-tetrahydroquinolines and analogues thereof

This invention concerns compounds having the Z-configuration of formula: ##STR1## or salts thereof, wherein R represents an optionally substituted aryl or heteroaryl radical, R.sup.1, R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, (C.sub.1 -C.sub.6 alkoxy)carbonyl, carboxy, hydroxy (C.sub.1 -C.sub.6)alkyl, halogen, halo(C.sub.1 -C.sub.6)alkyl, carboxy(C.sub.1 -C.sub.6)alkyl, optionally substituted aryl or heteroaryl or optionally substituted aralkyl or heteroarylalkyl; n represents O, 1 or 2; R.sup.4 and R.sup.5 each independently represent hydrogen or a substituent selected from lower alkyl, optionally substituted aryl and optionally substituted aralkyl or R.sup.4 and R.sup.5 are geminal C.sub.1 -C.sub.6 alkyl substituents and R.sup.6 is hydrogen or C.sub.1 -C.sub.6 alkyl which possess antiinflammatory activity.

The invention concerns compounds of formula I ##STR1## or a salt thereof, wherein R.sup.1 and R.sup.2 each independently represent hydrogen, lower alkyl, lower alkoxy, carboxyloweralkyl, carboxy, hydroxyloweralkyl, halogen, haloloweralkyl, lower alkoxycarbonyl, optionally substituted aryl or optionally substituted aralkyl, n represents an integer from 3 to 6; R.sup.3 represents hydrogen or single or multiple substitution on one or more of the aliphatic carbons by one or more substituents selected from lower alkyl, optionally substituted aryl and optionally substituted aralkyl; A represents a group of formula (i) or (ii) below:

Certain cyclopenta[b]pyridines and 5,6,7,8-tetrahydroquinolines having

The invention concerns compounds of formula ##STR1## or salts thereof; wherein Ar is an optionally substituted aryl radical;

1,4-dihydropyridines and their ability to inhibit blood platelet

The invention concerns compounds of formula ##STR1## or salts thereof; wherein:

1,4-dihydropyridines

The invention provides a method of relieving inflammation in a mammal inflicted with an imflammatory disease which method comprises treating said mammal with a therapeutically effective amount of a compound of formula I ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, loweralkyl, cycloloweralkyl, loweralkoxy, carboxy, hydroxyloweralkyl, halogen, haloloweralkyl, loweralkoxycarbonyl, aryl or aralkyl or 7-12 carbon atoms, or R.sup.1 and R.sup.2 taken together, or R.sup.2 and R.sup.3 taken together form a5,6, or 7 membered ring with the carbon atoms to which they are attached, which ring may be saturated or unsaturated and unsubstituted or substituted by loweralkyl or loweralkoxy, R.sup.4 represents hydrogen, loweralkyl, loweralkoxy, aryl or aralkyl of 7-12 carbon atoms, n is 1,2 or 3, m is 1,2 or 3, Ar represents phenyl which may be substituted by halogen, loweralkyl, loweralkoxy, haloloweralkyl, haloloweralkoxy, nitro, amino; cyano, loweralkylamino, diloweralkylamino, carboxy, loweralkoxycarbonyl, loweralkanoyl, loweralkanoylamino, aryl or aminoloweralkyl, X is NHSO.sub.2, NH, NHCO--, CH(OH), O, CO, S, SO or SO.sub.2, or a pharmaceutically acceptable salt thereof.

Pyridine derivatives

The invention concerns a new stable crystal form of anhydrous, crystalline 1,4-dihydro-2-(imidazol-1-ylmethyl)-6-methyl-4-(3-nitrophenyl)pyridine)-3, 5-dicarboxylic acid 3-ethyl 5-methyl diester hydrochloride, 'having a melting point greater than about 215.degree. C., an infra red spectrum (nujolmull) having sharp peaks at 3195 cm.sup.-1, 3100 cm.sup.-1, 2735 cm.sup.-1 and 2625 cm.sup.-1 and an x-ray powder diffraction pattern with specific peaks occurring at 2.theta.=12.3.degree. and 44.5.degree..'

Stable crystal form of

Certain anti-inflammatory cyclohepta[b]pyridines and analogs thereof

This invention concerns compounds of formula ##STR1## or salts thereof, wherein: Ar is an optionally substituted aryl radical;

1.4-Dihydropyridines

This invention concerns a method of treatment using 1,4-dihydropyridine derivatives having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R is aryl or heteroaryl;

Method of treating of preventing diseases using 1,4-dihydropyridines

Indoloquinolizines of the formula (I) ##STR1## and their pharmaceutically acceptable acid addition salts [wherein R.sup.1 represents hydrogen, lower alkyl or lower aralkyl, R.sup.2 and R.sup.3 each represent hydrogen, halogen, lower alkoxy or lower alkyl, R.sup.4 represents hydrogen, halogen or lower alkyl and R.sup.5 represents lower alkyl or aryl] possess antihypertensive activity.

Growing community of inventors

Maidenhead, United Kingdom

Albert Opalko